Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Radiology · Clear Cell Renal Cell Carcinoma

Imaging and Diagnostic Tests for ccRCC

At a Glance

Clear cell renal cell carcinoma (ccRCC) is typically diagnosed using multiphasic CT scans and MRIs rather than an immediate biopsy. Doctors use the Clear Cell Likelihood Score (ccLS) to evaluate these scans, predicting the probability of cancer and guiding treatment decisions.

The diagnosis of Clear Cell Renal Cell Carcinoma (ccRCC) relies heavily on high-tech imaging that allows doctors to “see” the unique characteristics of the tumor without an initial invasive procedure. Because ccRCC behaves differently than other kidney masses, radiologists use specific types of scans to look for its “fingerprints.”

Multiphasic Imaging: A Detailed View

To diagnose kidney cancer, doctors typically use multiphasic imaging—usually a CT scan or MRI. “Multiphasic” means the scan takes several sets of pictures at different times after a contrast agent (dye) is injected into your vein [1][2].

  • CT Scan: In a multiphasic CT, doctors measure how much of the dye the tumor “soaks up” (called enhancement). ccRCC tends to absorb a lot of dye very quickly, showing a much higher iodine concentration than other subtypes like papillary RCC [1][3].
  • MRI: An MRI is particularly good at looking for microscopic fat inside the tumor, which is a common feature of ccRCC but rare in other kidney cancers [4][5]. It also uses a technique called Diffusion-Weighted Imaging (DWI) to see how water molecules move through the tissue, helping to distinguish between different types of tumors [6][7].

The Clear Cell Likelihood Score (ccLS)

If you have an MRI, your doctor may use the Clear Cell Likelihood Score (ccLS). This is a standardized system, similar to a “weather report” for your kidney mass, that predicts the probability that a small mass is specifically ccRCC [8][9].

Score Meaning Action Often Considered
ccLS 1 or 2 Very unlikely to be ccRCC Active surveillance (a strict schedule of repeated scans to track growth) [10]
ccLS 3 Indeterminate (could be anything) Biopsy or closer monitoring [11]
ccLS 4 or 5 High probability of being ccRCC Surgery or treatment [10][12]

A high ccLS score (4 or 5) is often enough for a surgeon to recommend treatment without needing a biopsy first [13].

Distinguishing Benign from Malignant

One of the hardest jobs for a radiologist is telling the difference between ccRCC and benign (non-cancerous) masses:

  • Oncocytoma: This benign tumor often looks identical to cancer on standard scans [14]. While a “spoke-wheel” pattern or a central scar can sometimes be seen, these are not always present [15].
  • Angiomyolipoma: This is a benign tumor made of fat, blood vessels, and muscle. While most are easy to spot because of their fat content, “fat-poor” versions can mimic ccRCC on a CT scan [16].

To Biopsy or Not to Biopsy?

A renal mass biopsy (using a needle to take a small tissue sample) is not always required [17]. Many patients go straight to surgery if the imaging is clear. However, a biopsy may be recommended if [18][19]:

  • The imaging results are unclear (like a ccLS 3).
  • The doctor suspects the mass might be a different type of cancer that spread from elsewhere (metastasis).
  • You are considering Active Surveillance [20].
  • You are planning for Thermal Ablation (destroying the tumor with heat or cold) [19].

Looking Ahead: Molecular Imaging

New types of scans, like PET-CT using specialized “tracers” (such as Girentuximab), are being studied in clinical trials [21]. These tracers act like “homing pigeons” that attach specifically to a protein found on ccRCC cells, potentially making diagnosis much more accurate in the future [T-0S4BGVP3][22].

Common questions in this guide

What is the Clear Cell Likelihood Score (ccLS)?
The Clear Cell Likelihood Score is a standardized system used with MRI scans to predict the probability that a kidney mass is clear cell renal cell carcinoma. A score of 1 or 2 means cancer is very unlikely, while a 4 or 5 indicates a high probability of cancer.
Do I always need a biopsy to diagnose a kidney mass?
A biopsy is not always required to diagnose ccRCC. If multiphasic imaging or a high ccLS score strongly suggests cancer, many patients proceed directly to surgery. Biopsies are typically used when imaging is unclear or if treatments like thermal ablation or active surveillance are planned.
How does a multiphasic CT scan help diagnose ccRCC?
A multiphasic CT scan takes multiple pictures at different times after contrast dye is injected. Because ccRCC tumors have a rich blood supply, they absorb the dye very quickly, helping radiologists distinguish them from other types of kidney masses.
Can imaging scans tell the difference between ccRCC and a benign tumor?
Distinguishing ccRCC from benign tumors like oncocytomas or fat-poor angiomyolipomas can be challenging. However, specialized MRI techniques that detect microscopic fat or track water movement can help radiologists identify the mass more accurately without an invasive procedure.
What are molecular imaging and PET-CT scans for kidney cancer?
Molecular imaging involves new types of PET-CT scans that use specialized tracers, such as Girentuximab, to attach to specific proteins on ccRCC cells. While currently in clinical trials, these tracers act like homing signals to make diagnosing kidney tumors much more precise.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the Clear Cell Likelihood Score (ccLS) for my kidney mass, and what does it indicate about the chances of it being cancer?
  2. 2.Does my imaging show signs of 'microscopic fat' or specific 'enhancement patterns' that suggest ccRCC over other types?
  3. 3.Based on my scans, do you think a renal mass biopsy is necessary, or should we proceed directly to surgery?
  4. 4.Can the imaging distinguish this mass from a benign oncocytoma or an angiomyolipoma?
  5. 5.How might my results change if we used a specialized PET-CT scan like the Girentuximab tracer being studied in clinical trials?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Characterization of clear cell renal cell carcinoma and other renal tumors: evaluation of dual-energy CT using material-specific iodine and fat imaging.

    Udare A, Walker D, Krishna S, et al.

    European radiology 2020; (30(4)):2091-2102 doi:10.1007/s00330-019-06590-1.

    PMID: 31858204
  2. 2

    Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.

    Young JR, Coy H, Kim HJ, et al.

    AJR. American journal of roentgenology 2017; (208(4)):812-819 doi:10.2214/AJR.16.17152.

    PMID: 28125273
  3. 3

    Differentiation of Clear Cell Renal Cell Carcinoma From Other Subtypes and Fat-Poor Angiomyolipoma by Use of Quantitative Enhancement Measurement During Three-Phase MDCT.

    Kim SH, Kim CS, Kim MJ, et al.

    AJR. American journal of roentgenology 2016; (206(1)):W21-8 doi:10.2214/AJR.15.14666.

    PMID: 26700359
  4. 4

    Is fat quantification based on proton density fat fraction useful for differentiating renal tumor types?

    Altay C, Başara Akın I, Özgül HA, et al.

    Abdominal radiology (New York) 2025; (50(3)):1254-1265 doi:10.1007/s00261-024-04596-y.

    PMID: 39333411
  5. 5

    Fat status detection and histotypes differentiation in solid renal masses using Dixon technique.

    Sun J, Xing Z, Chen J, et al.

    Clinical imaging 2018; (51()):12-22 doi:10.1016/j.clinimag.2018.01.012.

    PMID: 29414519
  6. 6

    High signal renal tumors on DWI: the diagnostic value of morphological characteristics.

    Zhang H, Pan J, Shen Y, et al.

    Abdominal radiology (New York) 2019; (44(1)):239-246 doi:10.1007/s00261-018-1728-4.

    PMID: 30141057
  7. 7

    Usefulness of diffusion tensor imaging for the differentiation between low-fat angiomyolipoma and clear cell carcinoma of the kidney.

    Feng Q, Ma Z, Zhang S, Wu J

    SpringerPlus 2016; (5()):12 doi:10.1186/s40064-015-1627-x.

    PMID: 26759751
  8. 8

    Clear cell likelihood score may improve diagnosis and management of renal masses.

    Salles-Silva E, Lima EM, Amorim VB, et al.

    Abdominal radiology (New York) 2024; (49(12)):4494-4506 doi:10.1007/s00261-024-04415-4.

    PMID: 38900323
  9. 9

    Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging.

    Johnson BA, Kim S, Steinberg RL, et al.

    Urologic oncology 2019; (37(12)):941-946 doi:10.1016/j.urolonc.2019.07.023.

    PMID: 31540830
  10. 10

    Multicenter Evaluation of Multiparametric MRI Clear Cell Likelihood Scores in Solid Indeterminate Small Renal Masses.

    Schieda N, Davenport MS, Silverman SG, et al.

    Radiology 2022; (303(3)):590-599 doi:10.1148/radiol.211680.

    PMID: 35289659
  11. 11

    Diagnostic accuracy of the Clear Cell Likelihood Score and selected MRI parameters in the characterization of indeterminate renal masses - a single-institution study.

    Blachura T, Matusik PS, Kowal A, et al.

    Abdominal radiology (New York) 2024; (49(11)):3893-3901 doi:10.1007/s00261-024-04484-5.

    PMID: 38980404
  12. 12

    Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance.

    Rasmussen RG, Xi Y, Sibley RC, et al.

    AJR. American journal of roentgenology 2022; (218(1)):101-110 doi:10.2214/AJR.21.25979.

    PMID: 34286596
  13. 13

    Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Identify Clear Cell Renal Cell Carcinoma in cT1a Renal Masses.

    Canvasser NE, Kay FU, Xi Y, et al.

    The Journal of urology 2017; (198(4)):780-786 doi:10.1016/j.juro.2017.04.089.

    PMID: 28457802
  14. 14

    Palpable Abdominal Mass is a Renal Oncocytoma: Not All Large Renal Masses are Malignant.

    Dey S, Noyes SL, Uddin G, Lane BR

    Case reports in urology 2019; (2019()):6016870 doi:10.1155/2019/6016870.

    PMID: 31485367
  15. 15

    Asymptomatic Giant Right Renal Oncocytoma: A Case Report.

    Çevik G, Tozsin A, Erdoğan EG, et al.

    Cureus 2023; (15(1)):e34129 doi:10.7759/cureus.34129.

    PMID: 36843740
  16. 16

    Using the "2 standard deviations" rule with Dixon MRI to differentiate renal cell carcinoma types.

    Sun J, Xing Z, Pan L, et al.

    Clinical imaging 2023; (101()):113-120 doi:10.1016/j.clinimag.2023.06.011.

    PMID: 37329638
  17. 17

    Renal Mass Biopsy: Always, Sometimes, or Never?

    Kutikov A, Smaldone MC, Uzzo RG, et al.

    European urology 2016; (70(3)):403-6.

    PMID: 27085625
  18. 18

    Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.

    Mansour H, Tran-Dang MA, Walkden M, et al.

    Nature reviews. Urology 2025; (22(1)):8-25 doi:10.1038/s41585-024-00897-5.

    PMID: 38907039
  19. 19

    Diagnostic accuracy of percutaneous renal mass biopsy in patients undergoing robot-assisted partial nephrectomy for localized renal cell carcinoma.

    Timane JP, Petersson RD, Jepsen RK, Thomsen FF

    Urologic oncology 2025; (43(12)):708.e1-708.e6 doi:10.1016/j.urolonc.2025.09.002.

    PMID: 41016893
  20. 20

    Percutaneous renal mass biopsy: historical perspective, current status, and future considerations.

    Cotta BH, Meagher MF, Bradshaw A, et al.

    Expert review of anticancer therapy 2019; (19(4)):301-308 doi:10.1080/14737140.2019.1571915.

    PMID: 30656989
  21. 21

    [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

    Shuch B, Pantuck AJ, Bernhard JC, et al.

    The Lancet. Oncology 2024; (25(10)):1277-1287 doi:10.1016/S1470-2045(24)00402-9.

    PMID: 39270701
  22. 22

    First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.

    Hofman MS, Tran B, Feldman DR, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024; doi:10.2967/jnumed.123.267175.

    PMID: 38388517

This page explains ccRCC imaging and diagnostic tests for educational purposes only. Always consult your urologist or radiologist to interpret your specific scan results and determine the best diagnostic approach for your kidney mass.

Get notified when new evidence is published on Clear cell renal carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.